Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Methods Mol Biol. 2020;2097:197–209. doi: 10.1007/978-1-0716-0203-4_12

Fig. 5.

Fig. 5

In vitro cytotoxicity of the αCD3/αEGFR SMART-Exos for MDA-MB-468 (EGFR+) or MDA-MB-453 (EGFR−) cells. Nonactivated hPBMCs (effector cells) were incubated with MDA-MB-468 (EGFR+) and MDA-MB-453 (EGFR−) cells (target cells) at an E:T ratio of 10 for 40 h in the presence of αCD3/αEGFR SMART-Exos or a mixture (1:1) of αCD3 SMART-Exos and αEGFR SMART-Exos. After removing hPBMCs suspensions, cell viabilities of target cells were measured through MTT assays. (Adapted with permission from J. Am. Chem. Soc. 2018, 140, 48, 16,413–16,417. Copyright (2018) American Chemical Society)